Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruix, Jordi, Dr, Qin, Shukui, Prof, Merle, Philippe, Prof, Granito, Alessandro, MD, Huang, Yi-Hsiang, Prof, Bodoky, György, MD, Pracht, Marc, MD, Yokosuka, Osamu, Prof, Rosmorduc, Olivier, Prof, Breder, Valeriy, MD, Gerolami, René, Prof, Masi, Gianluca, MD, Ross, Paul J, FRCP, Song, Tianqiang, PhD, Bronowicki, Jean-Pierre, Prof, Ollivier-Hourmand, Isabelle, MD, Kudo, Masatoshi, Prof, Cheng, Ann-Lii, Prof, Llovet, Josep M, Prof, Finn, Richard S, MD, LeBerre, Marie-Aude, MSc, Baumhauer, Annette, MD, Meinhardt, Gerold, MD, Han, Guohong, Prof
Published in The Lancet (British edition) (07.01.2017)
Published in The Lancet (British edition) (07.01.2017)
Get full text
Journal Article